Comparative Pharmacology
Head-to-head clinical analysis: SEROQUEL versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROQUEL versus TOVALT ODT.
SEROQUEL vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at dopamine D2 and serotonin 5-HT2A receptors; also blocks histamine H1 and adrenergic α1 receptors.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
Initial: 25 mg twice daily; titrate by 25-50 mg twice daily on day 2 and 3 to target 300-400 mg daily in 2-3 divided doses. Maintenance: 400-800 mg daily. Maximum: 800 mg daily.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life approximately 7 hours for quetiapine; for metabolite N-desalkylquetiapine (norquetiapine), approximately 12 hours. Steady-state reached within 2 days.
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Primarily hepatic metabolism; <1% excreted unchanged renally. Metabolites excreted in urine (73%) and feces (20%).
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic